Leerink Partnrs Brokers Decrease Earnings Estimates for AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Agios Pharmaceuticals in a report released on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the biopharmaceutical company will post earnings per share of ($1.81) for the quarter, down from their prior estimate of ($1.78). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. Leerink Partnrs also issued estimates for Agios Pharmaceuticals' Q3 2025 earnings at ($1.87) EPS, Q4 2025 earnings at ($2.22) EPS, FY2025 earnings at ($7.64) EPS, FY2026 earnings at ($7.31) EPS and FY2027 earnings at ($2.43) EPS.

A number of other brokerages have also recently weighed in on AGIO. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 1st. Scotiabank cut their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday. Finally, HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded down $1.61 on Thursday, hitting $28.37. 305,561 shares of the stock were exchanged, compared to its average volume of 697,966. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 2.51 and a beta of 0.83. The company's 50-day moving average price is $29.72 and its two-hundred day moving average price is $37.65.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.93% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at about $33,000. GF Fund Management CO. LTD. purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $39,000. CWM LLC lifted its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares during the last quarter. Wingate Wealth Advisors Inc. acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth approximately $53,000. Finally, Sterling Capital Management LLC grew its stake in Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.